It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cepharanthine is a secondary metabolite isolated from Stephania. It has been reported that it has anti-conronaviruses activities including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Here, we assemble three Stephania genomes (S. japonica, S. yunnanensis, and S. cepharantha), propose the cepharanthine biosynthetic pathway, and assess the antiviral potential of compounds involved in the pathway. Among the three genomes, S. japonica has a near telomere-to-telomere assembly with one remaining gap, and S. cepharantha and S. yunnanensis have chromosome-level assemblies. Following by biosynthetic gene mining and metabolomics analysis, we identify seven cepharanthine analogs that have broad-spectrum anti-coronavirus activities, including SARS-CoV-2, Guangxi pangolin-CoV (GX_P2V), swine acute diarrhoea syndrome coronavirus (SADS-CoV), and porcine epidemic diarrhea virus (PEDV). We also show that two other genera, Nelumbo and Thalictrum, can produce cepharanthine analogs, and thus have the potential for antiviral compound discovery. Results generated from this study could accelerate broad-spectrum anti-coronavirus drug discovery.
Cepharanthine is a secondary metabolite isolated from Stephania with a variety of medicinal properties. Here, the authors assembled three Stephania genomes, propose cepharanthine biosynthetic pathway, and assess the antiviral potential of cepharanthine-related metabolites.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Chengdu University of Traditional Chinese Medicine, Institute of Herbgenomics, Chengdu, China (GRID:grid.411304.3) (ISNI:0000 0001 0376 205X)
2 Northeast Forestry University, College of Life Science, Harbin, China (GRID:grid.412246.7) (ISNI:0000 0004 1789 9091)
3 Beijing University of Chemical Technology, College of Life Science and Technology, Beijing, China (GRID:grid.48166.3d) (ISNI:0000 0000 9931 8406)
4 NHC Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
5 Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
6 Dali University, College of Pharmaceutical Science, Dali, China (GRID:grid.440682.c) (ISNI:0000 0001 1866 919X)
7 Hubei University of Chinese Medicine, College of Pharmacy, Wuhan, China (GRID:grid.257143.6) (ISNI:0000 0004 1772 1285)
8 Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China (GRID:grid.411304.3) (ISNI:0000 0001 0376 205X)
9 Wuhan Botanical Garden, Chinese Academy of Sciences, Wuhan, China (GRID:grid.458515.8) (ISNI:0000 0004 1770 1110)